R&D at other companies
Segments
By segment
See fullOther financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s R&D?
- Spyre Therapeutics, Inc. (SYRE) reported R&D of $60.41M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s R&D changed year-over-year?
- Spyre Therapeutics, Inc.'s R&D increased by 45.1% year-over-year, from $41.62M to $60.41M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s R&D?
- Over 4 years (2021 to 2025), Spyre Therapeutics, Inc.'s R&D has grown at a 31.7% compound annual growth rate (CAGR), from $57.07M to $171.65M.
- What does R&D mean?
- The money spent on creating and testing new products or scientific breakthroughs.
- How do you interpret R&D?
- Higher spending reflects a commitment to pipeline expansion, though it reduces short-term profitability.
- How does R&D compare across companies?
- High R&D intensity is standard for clinical-stage biotech companies compared to mature pharmaceutical firms.